symbol,statement_type,period_end,line_item,value
PPLPHARMA.NS,income,2025-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Tax Rate For Calcs,0.3
PPLPHARMA.NS,income,2025-03-31 00:00:00,Normalized EBITDA,16525700000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Total Unusual Items,0.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Total Unusual Items Excluding Goodwill,0.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,911300000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Reconciled Depreciation,8163400000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Reconciled Cost Of Revenue,32316500000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,EBITDA,16525700000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,EBIT,8362300000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Net Interest Income,-4215900000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Interest Expense,4215900000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Interest Income,
PPLPHARMA.NS,income,2025-03-31 00:00:00,Normalized Income,911300000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,911300000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Total Expenses,85226900000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Rent Expense Supplemental,
PPLPHARMA.NS,income,2025-03-31 00:00:00,Diluted Average Shares,1340147059.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Basic Average Shares,1320724638.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Diluted EPS,0.68
PPLPHARMA.NS,income,2025-03-31 00:00:00,Basic EPS,0.69
PPLPHARMA.NS,income,2025-03-31 00:00:00,Diluted NI Availto Com Stockholders,911300000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Net Income Common Stockholders,911300000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Net Income,911300000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Minority Interests,0.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Net Income Including Noncontrolling Interests,911300000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Net Income Continuous Operations,911300000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Tax Provision,3235100000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Pretax Income,4146400000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Other Non Operating Income Expenses,1348100000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Special Income Charges,0.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Other Special Charges,
PPLPHARMA.NS,income,2025-03-31 00:00:00,Write Off,
PPLPHARMA.NS,income,2025-03-31 00:00:00,Impairment Of Capital Assets,
PPLPHARMA.NS,income,2025-03-31 00:00:00,Restructuring And Mergern Acquisition,
PPLPHARMA.NS,income,2025-03-31 00:00:00,Net Non Operating Interest Income Expense,-4215900000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Total Other Finance Cost,
PPLPHARMA.NS,income,2025-03-31 00:00:00,Interest Expense Non Operating,4215900000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Interest Income Non Operating,
PPLPHARMA.NS,income,2025-03-31 00:00:00,Operating Income,6284900000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Operating Expense,52910400000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Other Operating Expenses,21672300000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Depreciation And Amortization In Income Statement,8163400000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Depreciation Income Statement,8163400000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Research And Development,
PPLPHARMA.NS,income,2025-03-31 00:00:00,Selling General And Administration,
PPLPHARMA.NS,income,2025-03-31 00:00:00,Selling And Marketing Expense,
PPLPHARMA.NS,income,2025-03-31 00:00:00,General And Administrative Expense,
PPLPHARMA.NS,income,2025-03-31 00:00:00,Rent And Landing Fees,
PPLPHARMA.NS,income,2025-03-31 00:00:00,Gross Profit,59195300000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Cost Of Revenue,32316500000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Total Revenue,91511800000.0
PPLPHARMA.NS,income,2025-03-31 00:00:00,Operating Revenue,91511800000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Tax Effect Of Unusual Items,-188370000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Tax Rate For Calcs,0.3
PPLPHARMA.NS,income,2024-03-31 00:00:00,Normalized EBITDA,14311400000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Total Unusual Items,-627900000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-627900000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,178200000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Reconciled Depreciation,7405600000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Reconciled Cost Of Revenue,29540000000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,EBITDA,13683500000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,EBIT,6277800000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Net Interest Income,-4484900000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Interest Expense,4484900000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Interest Income,119200000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Normalized Income,617730000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,178200000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Total Expenses,77154700000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Rent Expense Supplemental,315900000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Diluted Average Shares,1272857143.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Basic Average Shares,1272857143.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Diluted EPS,0.14
PPLPHARMA.NS,income,2024-03-31 00:00:00,Basic EPS,0.14
PPLPHARMA.NS,income,2024-03-31 00:00:00,Diluted NI Availto Com Stockholders,178200000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Net Income Common Stockholders,178200000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Net Income,178200000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Minority Interests,0.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Net Income Including Noncontrolling Interests,178200000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Net Income Continuous Operations,178200000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Tax Provision,1614700000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Pretax Income,1792900000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Other Non Operating Income Expenses,1753900000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Special Income Charges,-627900000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Other Special Charges,627900000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Write Off,5800000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Impairment Of Capital Assets,
PPLPHARMA.NS,income,2024-03-31 00:00:00,Restructuring And Mergern Acquisition,0.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Net Non Operating Interest Income Expense,-4484900000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Total Other Finance Cost,15400000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Interest Expense Non Operating,4484900000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Interest Income Non Operating,119200000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Operating Income,4556900000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Operating Expense,47614700000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Other Operating Expenses,19914000000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Depreciation And Amortization In Income Statement,7405700000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Depreciation Income Statement,7405700000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Research And Development,1006700000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Selling General And Administration,5668800000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Selling And Marketing Expense,3041300000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,General And Administrative Expense,2627500000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Rent And Landing Fees,315900000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Gross Profit,52171600000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Cost Of Revenue,29540000000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Total Revenue,81711600000.0
PPLPHARMA.NS,income,2024-03-31 00:00:00,Operating Revenue,81711600000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Tax Effect Of Unusual Items,-14640000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Tax Rate For Calcs,0.3
PPLPHARMA.NS,income,2023-03-31 00:00:00,Normalized EBITDA,8991300000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Total Unusual Items,-48800000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-48800000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,-1864600000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Reconciled Depreciation,6766900000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Reconciled Cost Of Revenue,30001800000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,EBITDA,8942500000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,EBIT,2175600000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Net Interest Income,-3425400000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Interest Expense,3377100000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Interest Income,16400000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Normalized Income,-1830440000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,-1864600000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Total Expenses,70803800000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Rent Expense Supplemental,321000000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Diluted Average Shares,1212672645.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Basic Average Shares,1212672645.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Diluted EPS,-1.54
PPLPHARMA.NS,income,2023-03-31 00:00:00,Basic EPS,-1.54
PPLPHARMA.NS,income,2023-03-31 00:00:00,Diluted NI Availto Com Stockholders,-1864600000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Net Income Common Stockholders,-1864600000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Net Income,-1864600000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Minority Interests,
PPLPHARMA.NS,income,2023-03-31 00:00:00,Net Income Including Noncontrolling Interests,-1864600000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Net Income Continuous Operations,-1864600000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Tax Provision,663100000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Pretax Income,-1201500000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Other Non Operating Income Expenses,1101400000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Special Income Charges,-74400000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Other Special Charges,4800000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Write Off,0.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Impairment Of Capital Assets,
PPLPHARMA.NS,income,2023-03-31 00:00:00,Restructuring And Mergern Acquisition,69600000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Net Non Operating Interest Income Expense,-3425400000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Total Other Finance Cost,64700000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Interest Expense Non Operating,3377100000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Interest Income Non Operating,16400000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Operating Income,-479700000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Operating Expense,40802000000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Other Operating Expenses,8804400000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Depreciation And Amortization In Income Statement,6766900000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Depreciation Income Statement,6766900000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Research And Development,863600000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Selling General And Administration,5553800000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Selling And Marketing Expense,3236900000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,General And Administrative Expense,2316900000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Rent And Landing Fees,321000000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Gross Profit,40322300000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Cost Of Revenue,30001800000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Total Revenue,70324100000.0
PPLPHARMA.NS,income,2023-03-31 00:00:00,Operating Revenue,70324100000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Tax Effect Of Unusual Items,14274341.209947
PPLPHARMA.NS,income,2022-03-31 00:00:00,Tax Rate For Calcs,0.224793
PPLPHARMA.NS,income,2022-03-31 00:00:00,Normalized EBITDA,12535900000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Total Unusual Items,63500000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Total Unusual Items Excluding Goodwill,63500000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,3759600000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Reconciled Depreciation,5861800000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Reconciled Cost Of Revenue,26803100000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,EBITDA,12599400000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,EBIT,6737600000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Net Interest Income,-1975700000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Interest Expense,1887800000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Interest Income,6800000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Normalized Income,3710374341.209947
PPLPHARMA.NS,income,2022-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,3759600000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Total Expenses,61063400000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Rent Expense Supplemental,282500000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Diluted Average Shares,1216975687.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Basic Average Shares,1216975687.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Diluted EPS,3.089298
PPLPHARMA.NS,income,2022-03-31 00:00:00,Basic EPS,3.089298
PPLPHARMA.NS,income,2022-03-31 00:00:00,Diluted NI Availto Com Stockholders,3759600000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Net Income Common Stockholders,3759600000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Net Income,3759600000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Minority Interests,
PPLPHARMA.NS,income,2022-03-31 00:00:00,Net Income Including Noncontrolling Interests,3759600000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Net Income Continuous Operations,3759600000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Tax Provision,1090200000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Pretax Income,4849800000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Other Non Operating Income Expenses,2351200000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Special Income Charges,-167800000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Other Special Charges,5400000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Write Off,11600000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Impairment Of Capital Assets,0.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Restructuring And Mergern Acquisition,150800000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Net Non Operating Interest Income Expense,-1975700000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Total Other Finance Cost,94700000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Interest Expense Non Operating,1887800000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Interest Income Non Operating,6800000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Operating Income,3651600000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Operating Expense,34260300000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Other Operating Expenses,7041600000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Depreciation And Amortization In Income Statement,5861800000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Depreciation Income Statement,5861800000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Research And Development,1283400000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Selling General And Administration,4768300000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Selling And Marketing Expense,2856200000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,General And Administrative Expense,1912100000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Rent And Landing Fees,282500000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Gross Profit,37911900000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Cost Of Revenue,26803100000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Total Revenue,64715000000.0
PPLPHARMA.NS,income,2022-03-31 00:00:00,Operating Revenue,64715000000.0
PPLPHARMA.NS,income,2021-03-31 00:00:00,Tax Effect Of Unusual Items,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Tax Rate For Calcs,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Normalized EBITDA,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Total Unusual Items,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Total Unusual Items Excluding Goodwill,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Reconciled Depreciation,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Reconciled Cost Of Revenue,
PPLPHARMA.NS,income,2021-03-31 00:00:00,EBITDA,
PPLPHARMA.NS,income,2021-03-31 00:00:00,EBIT,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Net Interest Income,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Interest Expense,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Interest Income,207000000.0
PPLPHARMA.NS,income,2021-03-31 00:00:00,Normalized Income,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Total Expenses,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Rent Expense Supplemental,110000000.0
PPLPHARMA.NS,income,2021-03-31 00:00:00,Diluted Average Shares,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Basic Average Shares,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Diluted EPS,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Basic EPS,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Diluted NI Availto Com Stockholders,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Net Income Common Stockholders,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Otherunder Preferred Stock Dividend,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Net Income,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Minority Interests,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Net Income Including Noncontrolling Interests,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Net Income Continuous Operations,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Tax Provision,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Pretax Income,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Other Non Operating Income Expenses,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Special Income Charges,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Other Special Charges,54100000.0
PPLPHARMA.NS,income,2021-03-31 00:00:00,Write Off,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Impairment Of Capital Assets,374300000.0
PPLPHARMA.NS,income,2021-03-31 00:00:00,Restructuring And Mergern Acquisition,451900000.0
PPLPHARMA.NS,income,2021-03-31 00:00:00,Net Non Operating Interest Income Expense,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Total Other Finance Cost,47100000.0
PPLPHARMA.NS,income,2021-03-31 00:00:00,Interest Expense Non Operating,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Interest Income Non Operating,207000000.0
PPLPHARMA.NS,income,2021-03-31 00:00:00,Operating Income,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Operating Expense,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Other Operating Expenses,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Depreciation And Amortization In Income Statement,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Depreciation Income Statement,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Research And Development,691400000.0
PPLPHARMA.NS,income,2021-03-31 00:00:00,Selling General And Administration,1837300000.0
PPLPHARMA.NS,income,2021-03-31 00:00:00,Selling And Marketing Expense,1298800000.0
PPLPHARMA.NS,income,2021-03-31 00:00:00,General And Administrative Expense,538500000.0
PPLPHARMA.NS,income,2021-03-31 00:00:00,Rent And Landing Fees,110000000.0
PPLPHARMA.NS,income,2021-03-31 00:00:00,Gross Profit,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Cost Of Revenue,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Total Revenue,
PPLPHARMA.NS,income,2021-03-31 00:00:00,Operating Revenue,
